PI Industries Ltd.
PI Industries Ltd.
Announced Date: April 2023
Value: USD 38 million
o3 Capital acted as the exclusive financial advisor to PI Industries Limited on its acquisition of Archimica S.p.A.
PI Health Sciences Limited (“PIHS”), a 100% subsidiary of PI Industries Limited (“PI Industries”), one of India’s leading players in Agri-sciences and CSM industry, has acquired 100% stake in Archimica S.p.A. for USD 38 million.
Incorporated in 1947, PI Industries (BSE: 523642, NSE: PIIND, ISIN ID: INE603J01030) has been a leader in Agri-sciences segment. It is known for best-in-class manufacturing, quality, and EHS practices. It is on a strategic path of diversification and envisions the Pharma vertical as one of the key pillars for future growth. This acquisition is aligned with its strategic objective of building a differentiated CDMO offering across the pharma value chain.
Archimica is an Italy-based, highly reputable small molecule API manufacturer and a Contract Development & Manufacturing organisation (CDMO) servicing over 60 marquee customers in more than 30 countries. Archimica owns 24 US DMFs, GMP manufacturing facility for APIs and Intermediates across wide therapeutic and substance classes such as Oncology, Anti Ulcer, Anti Arthritis. Archimica’s manufacturing facility near Milan (Italy) is certified by major regulators such as USFDA and AIFA among others.
Mayank Singhal, Vice Chairman and Managing Director of PI Industries Limited. said, “We are excited about the acquisition as it marks a solid and accelerated beginning of PI’s journey in the pharma space. The acquisition is aligned with PI’s approach of working with global innovators and being at the forefront of innovation, science, technology and human ingenuity to create transformative solutions in life sciences with the purpose of reimagining a healthier planet. I compliment PI’s leadership team and external advisors in fructifying this strategic opportunity.”
This deal marks o3 Capital's 12th deal closure in the Healthcare & Lifesciences space in the last 2 years. The deal reiterates o3 Capital’s strong credentials in the Healthcare and Lifesciences segment (52 deal closures till date) and our ability to consummate deals in the API and CDMO space within the Lifesciences industry.